117 related articles for article (PubMed ID: 30883591)
1. Outcomes of protease inhibitor-based antiretroviral therapy amongst children and associated-factors in Yaoundé, Cameroon.
Njom Nlend AE; Guessong CO; Nga Motaze AC; Soffo C; Koki Ndombo PO; Tsambang L; Fokam J
PLoS One; 2019; 14(3):e0213900. PubMed ID: 30883591
[TBL] [Abstract][Full Text] [Related]
2. Immuno-virological response and associated factors amongst HIV-1 vertically infected adolescents in Yaoundé-Cameroon.
Fokam J; Billong SC; Jogue F; Moyo Tetang Ndiang S; Nga Motaze AC; Paul KN; Njom Nlend AE
PLoS One; 2017; 12(11):e0187566. PubMed ID: 29112991
[TBL] [Abstract][Full Text] [Related]
3. Viral suppression in adults, adolescents and children receiving antiretroviral therapy in Cameroon: adolescents at high risk of virological failure in the era of "test and treat".
Fokam J; Sosso SM; Yagai B; Billong SC; Djubgang Mbadie RE; Kamgaing Simo R; Edimo SV; Nka AD; Tiga Ayissi A; Yimga JF; Takou D; Moudourou S; Ngo Nemb M; Nfetam Elat JB; Santoro MM; Perno CF; Colizzi V; Ndjolo A
AIDS Res Ther; 2019 Nov; 16(1):36. PubMed ID: 31744517
[TBL] [Abstract][Full Text] [Related]
4. Determinants of switch to paediatric second-line antiretroviral therapy after first-line failure in Cameroon.
Njom-Nlend AE; Efouba N; Brunelle Sandie A; Fokam J
Trop Med Int Health; 2021 Aug; 26(8):927-935. PubMed ID: 33905593
[TBL] [Abstract][Full Text] [Related]
5. Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
Fokam J; Nka AD; Mamgue Dzukam FY; Efakika Gabisa J; Bouba Y; Tommo Tchouaket MC; Ka'e AC; Ngoufack Jagni Semengue E; Takou D; Moudourou S; Fainguem N; Pabo W; Nayang Mundo RA; Kengni Ngueko AM; Ambe Chenwi C; Flore Yimga J; Nnomo Zam MK; Simo Kamgaing R; Tangimpundu C; Kamgaing N; Njom-Nlend AE; Ndombo Koki P; Kesseng D; Ndiang Tetang S; Kembou E; Ebiama Lifanda L; Pamen B; Ketchaji A; Saounde Temgoua E; Billong SC; Zoung-Kanyi Bissek AC; Hadja H; Halle EG; Colizzi V; Perno CF; Sosso SM; Ndjolo A
Medicine (Baltimore); 2023 May; 102(20):e33737. PubMed ID: 37335723
[TBL] [Abstract][Full Text] [Related]
6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
[TBL] [Abstract][Full Text] [Related]
8. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.
Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L
PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576
[TBL] [Abstract][Full Text] [Related]
9. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
[TBL] [Abstract][Full Text] [Related]
11. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.
Reitz C; Coovadia A; Ko S; Meyers T; Strehlau R; Sherman G; Kuhn L; Abrams EJ
J Infect Dis; 2010 Apr; 201(8):1121-31. PubMed ID: 20214476
[TBL] [Abstract][Full Text] [Related]
12. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
13. Protease inhibitor therapy in HIV-infected children.
Feingold AR; Rutstein RM; Meislich D; Brown T; Rudy BJ
AIDS Patient Care STDS; 2000 Nov; 14(11):589-93. PubMed ID: 11155900
[TBL] [Abstract][Full Text] [Related]
14. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
Mocroft A; Phillips AN; Miller V; Gatell J; van Lunzen J; Parkin JM; Weber R; Roge B; Lazzarin A; Lundgren JD;
AIDS; 2001 Jan; 15(2):201-9. PubMed ID: 11216928
[TBL] [Abstract][Full Text] [Related]
15. HIV treatment outcomes following antiretroviral therapy initiation and monitoring: A workplace program in Papua, Indonesia.
Limmade Y; Fransisca L; Rodriguez-Fernandez R; Bangs MJ; Rothe C
PLoS One; 2019; 14(2):e0212432. PubMed ID: 30802257
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of early initiated antiretroviral therapy in sub-Saharan children: a Cameroonian cohort study (ANRS-12140 Pediacam study, 2008-2013, Cameroon).
Ndongo FA; Tejiokem MC; Penda CI; Ndiang ST; Ndongo JA; Guemkam G; Sofeu CL; Tagnouokam-Ngoupo PA; Kfutwah A; Msellati P; Faye A; Warszawski J
BMC Pediatr; 2021 Apr; 21(1):189. PubMed ID: 33882903
[TBL] [Abstract][Full Text] [Related]
17. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
18. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral use in Italian children with perinatal HIV infection over a 14-year period.
Chiappini E; Galli L; Tovo PA; Gabiano C; Lisi C; Giacomet V; Bernardi S; Esposito S; Rosso R; Giaquinto C; Badolato R; Guarino A; Maccabruni A; Masi M; Cellini M; Salvini F; Di Bari C; Dedoni M; Dodi I; de Martino M;
Acta Paediatr; 2012 Jul; 101(7):e287-95. PubMed ID: 22452359
[TBL] [Abstract][Full Text] [Related]
20. Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis.
Gumede SB; Fischer A; Venter WDF; Lalla-Edward ST
S Afr Med J; 2019 Nov; 109(12):919-926. PubMed ID: 31865953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
